Breaking News
December 17, 2018 - How the Mediterranean Diet Can Help Women’s Hearts
December 17, 2018 - Sustained connections associated with symptoms of autism
December 17, 2018 - Concussion rates among young football players were higher than previously reported
December 17, 2018 - Cresco Labs granted approval to operate marijuana dispensary in Ohio
December 17, 2018 - Study provides insight into health risks facing new mothers
December 17, 2018 - AMSBIO expands Wnt signaling pathway product range to aid research
December 16, 2018 - Surgical treatment unnecessary for many prostate cancer patients
December 16, 2018 - Excess weight responsible for cancers globally finds report
December 16, 2018 - Regular sex associated with greater enjoyment of life in seniors
December 16, 2018 - Social stigma contributes to poor mental health in the autistic community
December 16, 2018 - Multidisciplinary team successfully performs complex surgery on patient suffering from enlarged skull
December 16, 2018 - Experts analyze data that can guide antidepressant discontinuation
December 16, 2018 - Menlo Therapeutics’ Successful Phase 2 Clinical Trial of Serlopitant Demonstrates Reduction of Pruritus Associated with Psoriasis
December 16, 2018 - Siblings of children with autism or ADHD are at elevated risk for both disorders
December 16, 2018 - New project aims to understand why and how metabolic disorders develop in patients
December 16, 2018 - Diets containing GM maize have no harmful effects on health or metabolism of rats
December 16, 2018 - Are doctors and teachers confusing immaturity and attention deficit?
December 16, 2018 - Hearing loss linked with increased risk for premature death
December 16, 2018 - Chromatrap buffer reagents for lysing cells offer many benefits
December 16, 2018 - Young Breast Cancer Patients Face Higher Risk for Osteoporosis
December 16, 2018 - 3-D printing offers helping hand to people with arthritis
December 16, 2018 - Community Health Choice helps manage complex and chronic care conditions
December 16, 2018 - Regular trips out could dramatically reduce depression in older age
December 16, 2018 - CWRU to use VivaLNK’s Vital Scout device for stress study in student athletes
December 16, 2018 - ‘Easy Way Out’? Stigma May Keep Many From Weight Loss Surgery
December 16, 2018 - Gout drug may protect against chronic kidney disease
December 16, 2018 - Talking about memories enhances the wellbeing of older and younger people
December 16, 2018 - Occupational exposure to pesticides increases risk for cardiovascular disease among Latinos
December 16, 2018 - A biomarker in the brain’s circulation system may be Alzheimer’s earliest warning
December 16, 2018 - Magnesium may play important role in optimizing vitamin D levels, study shows
December 16, 2018 - The effect of probiotics on intestinal flora of premature babies
December 16, 2018 - Parents spend more time talking with kids about mechanics of using mobile devices
December 16, 2018 - Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
December 16, 2018 - Arterial stiffness may predict dementia risk
December 16, 2018 - Study explores link between work stress and increased cancer risk
December 16, 2018 - Sex work criminalization linked to incidences of violence finds study
December 16, 2018 - Johns Hopkins researchers discover swarming behavior in fish-dwelling parasite
December 16, 2018 - Schistosomiasis prevention and treatment could help control HIV
December 16, 2018 - Early postpartum opioids linked with persistent usage
December 16, 2018 - Johns Hopkins researchers identify molecular causes of necrotizing enterocolitis in preemies
December 16, 2018 - Advanced illumination expands capabilities of light-sheet microscopy
December 16, 2018 - Alzheimer’s could possibly be spread via contaminated neurosurgery
December 16, 2018 - Unraveling the complexity of cancer biology can prompt new avenues for drug development
December 16, 2018 - Inflammatory Bowel Disease, Prostate Cancer Linked
December 16, 2018 - Cannabis youth prevention strategy should target mental wellbeing
December 15, 2018 - Recent developments and challenges in hMAT inhibitors
December 15, 2018 - Sewage bacteria found lurking in Hudson River sediments
December 15, 2018 - CDC selects UMass Amherst biostatistician model that helps predict influenza outbreaks
December 15, 2018 - Researchers reveal brain mechanism that drives itch-evoked scratching behavior
December 15, 2018 - New computer model helps predict course of the disease in prostate cancer patients
December 15, 2018 - Obesity to Blame for Almost 1 in 25 Cancers Worldwide
December 15, 2018 - How the brain tells you to scratch that itch
December 15, 2018 - New findings could help develop new immunotherapies against cancer
December 15, 2018 - World’s largest AI-powered medical research network launched by OWKIN
December 15, 2018 - Young people suffering chronic pain battle isolation and stigma as they struggle to forge their identities
December 15, 2018 - Lifespan extension at low temperatures depends on individual’s genes, study shows
December 15, 2018 - New ingestible capsule can be controlled using Bluetooth wireless technology
December 15, 2018 - Researchers uncover microRNAs involved in the control of social behavior
December 15, 2018 - Research offers hope for patients with serious bone marrow cancer
December 15, 2018 - Link between poverty and obesity is only about 30 years old, study shows
December 15, 2018 - Mass spectrometry throws light on old case of intentional heavy metal poisoning
December 15, 2018 - BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis
December 15, 2018 - Study finds that in treating obesity, one size does not fit all
December 15, 2018 - Tenacity and flexibility help maintain psychological well-being, mobility in older people
December 15, 2018 - Study reveals role of brain mechanism in memory recall
December 15, 2018 - High levels of oxygen encourage the brain to remain in deep, restorative sleep
December 15, 2018 - Experimental HIV vaccine strategy works in non-human primates, research shows
December 15, 2018 - Genetically modified pigs could limit replication of classical swine fever virus, study shows
December 15, 2018 - FDA Approves Herzuma (trastuzumab-pkrb), a Biosimilar to Herceptin
December 15, 2018 - Cost and weight-loss potential matter most to bariatric surgery patients
December 15, 2018 - Cancer Research UK and AstraZeneca open new Functional Genomics Centre
December 15, 2018 - New research lays out potential path for treatment of Huntington’s disease
December 15, 2018 - Prestigious R&D 100 Award presented to Leica Microsystems
December 15, 2018 - Study shows septin proteins detect and kill gut pathogen, Shigella
December 15, 2018 - Study sheds new light on disease-spreading mosquitoes
December 15, 2018 - 2017 Saw Slowing in National Health Care Spending
December 15, 2018 - Monitoring movement reflects efficacy of mandibular splint
December 15, 2018 - Study supports BMI as useful tool for assessing obesity and health
December 15, 2018 - Self-guided, internet-based therapy platforms effectively reduce depression
December 15, 2018 - Organically farmed food has bigger climate impact than conventional food production
FDA approves new combination therapy for acute myeloid leukemia

FDA approves new combination therapy for acute myeloid leukemia

image_pdfDownload PDFimage_print

Older patients with acute myeloid leukemia (AML) often aren’t healthy enough to receive intensive chemotherapy, and gentler treatments aren’t very effective in treating this aggressive blood cancer.

But a new option – a combination of a standard drug and the novel agent venetoclax – has been granted accelerated approval by the Food and Drug Administration for such patients after a large, multicenter phase 1 clinical trial showed the combination had “promising efficacy” and was well tolerated in older AML patients.

“I think it’s likely to become a standard for patients in this situation who have AML but can’t tolerate induction therapy” with harsher chemotherapy regimens, said Anthony Letai, MD, PhD, a medical oncologist at Dana-Farber Cancer Institute. Letai, who has carried out key research on inhibition of the BCL-2 pathway, leading to drugs like venetoclax (Venclexta), is corresponding author of a recent report in Blood on the results of an industry-sponsored phase 1 clinical trial.

The FDA approval is for use of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine for treatment of patients with newly diagnosed AML who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

The median age of people diagnosed with AML is 67. Patients who are considered fit enough are treated with “induction” therapy aimed at putting the disease in remission, followed by “consolidation” therapy with additional chemotherapy or a stem cell transplant. If successful, that two-step process can cure up to 40 percent of patients, said Letai. “But only a minority of patients are eligible to begin with” because of advanced age or because they have other conditions, such as heart disease, that increases their risk of death.

As a compromise, these patients may be treated with lower-intensity drugs called hypomethylating agents, such as azacitidine and decitabine. Letai said these drugs are “relatively nontoxic, but not that effective.” They induce remissions only in about 20 percent of patients, and often require several months of treatment to achieve remission, he said. They are rarely curative, with patients having a median survival of less than a year.

In an effort to improve this situation, the clinical trial paired hypomethylating agents with venetoclax, the first of a new class of targeted drugs called BCL-2 inhibitors that destroy cancer cells by attacking BCL-2, a “survival protein” they rely on to survive and multiply. Important advances in understanding BCL-2’s role in cancer and how it could be blocked to kill cancer cells was conducted in Letai’s Dana-Farber laboratory. Venetoclax, sold under the name Venclexta, was first approved in 2016 to treat certain patients with chronic lymphocytic leukemia (CLL) and its use has been expanded in those patients more recently.

Letai and Marina Konopleva, MD, PhD, of MD Anderson Cancer Center, in collaboration with researchers at the pharmaceutical company AbbVie, focused on how inhibiting BCL-2 in AML might be a new approach to treating the disease. Initial human trials with a BCL-2 inhibitor showed that as a single agent it had activity in patients with AML, but the effects weren’t robust.

Still, the rationale was promising. So, the researchers and AbbVie scientists created a clinical trial combining venetoclax at varying dosages with a hypomethylating drug – azacitidine or decitabine. The report in Blood demonstrates that the pairing of the two drugs is safe and relatively tolerable in AML patients not healthy enough for standard induction chemotherapy.

The trial included 145 patients ages 65 and above who received venetoclax and decitabine or azacytidine as initial therapy. The overall response rate – complete responses plus complete responses with incomplete blood count recovery – was 67 percent. Patients who were older (75 years or above) and who had poor-risk pathological features in their cancer cells had a CR rate of 60 percent and a CR plus CRi rate of 65 percent.

The median overall survival has not been reached for patients receiving 400 mg of venetoclax. For patients receiving all dosages, median overall survival was 17.5 months.

Also encouraging, said Letai, was that responses occurred more rapidly with the combination therapy than is typical with hypomethylating agents alone.

A phase 3 trial that is underway is comparing venetoclax and azacytidine with azacytidine as a single agent.

This trial was supported by AbbVie and Genentech, which are jointly developing venetoclax.

The FDA approval “marks a significant advance for people with acute myeloid leukemia, a highly aggressive and difficult-to-treat blood cancer,” said Sandra Horning, MD, chief medical officer at Genentech.

Source:

https://www.dana-farber.org/newsroom/news-releases/2018/venetoclax-combination-approved-for-elderly-aml/

Tagged with:

About author

Related Articles